UPDATE 1-Biogen revenue climbs; Spinraza, Tecfidera sales miss

(Adds details on drug sales, share price)

April 24 (Reuters) – Drug developer Biogen Inc reported a 11.4 percent rise in quarterly revenue as sales of key drugs Tecfidera and Spinraza climbed, albeit at a weaker-than-expected pace.

The company’s top-earning multiple sclerosis drug Tecfidera brought in a revenue of $987 million in the quarter, falling short of analyst estimate of $1.02 billion.

Sales of spinal muscular atrophy treatment Spinraza were $364 million, missing estimate of $381.55 million.

Net income attributable to shareholders rose to $1.17 billion in the first quarter ended March 31, or $5.54 per share, from $747.6 million or $3.46 a share, a year earlier.

Revenue rose 11.4 percent to $3.13 billion.

Shares of the company were marginally down at $258.79 in premarket trading. (Reporting by Mrinalini Krothapalli and Tamara Mathias; Editing by Amrutha Gayathri)

Learn More about forex signals providers

What do you think?

0 points
Upvote Downvote

Total votes: 0

Upvotes: 0

Upvotes percentage: 0.000000%

Downvotes: 0

Downvotes percentage: 0.000000%

Swatch CEO Hayek sees double digit growth continuing this year – CNBC

Salesforce announces $2.2 billion French investment as Macron meets Trump